Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-02-14 02:07:53 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | clinical trial, resource | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-02-14 02:07:23 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | clinical trial, resource | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-02-14 02:07:53 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | clinical trial, resource | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-02-14 02:07:53 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-02-14 02:07:23 | 0 | ||||
|
Diabetes Control and Complications Trial Resource Report Resource Website |
Diabetes Control and Complications Trial (RRID:SCR_006805) | DCCT | data or information resource, clinical trial, database, resource | Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk | blood glucose, adolescent, young human, middle adult human, longitudinal, eye disease, kidney disease, nerve disease, cardiovascular disease, heart attack, stroke, blood pressure, blood lipid, complication |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository is related to: Epidemiology of Diabetes Interventions and Complications is related to: Epidemiology of Diabetes Interventions and Complications is related to: NIDDK Information Network (dkNET) has parent organization: National Diabetes Information Clearinghouse |
Type 1 diabetes, Diabetes | NIDDK | nlx_152798 | SCR_006805 | DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study | 2026-02-14 02:07:57 | 0 | ||||||
|
Frequent Hemodialysis Network Nocturnal Trial Resource Report Resource Website |
Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) | FHN Nocturnal Trial | clinical trial, resource | Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia | hemodialysis, home, adult human, kidney, kidney disease |
is listed by: ClinicalTrials.gov is related to: Frequent Hemodialysis Network Daily Trial is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
End Stage Renal Disease, Hemodialysis | NIDDK | PMID:21775973 PMID:17164834 PMID:17699439 |
nlx_152829 | SCR_007014 | Frequent Hemodialysis Network (FHN) Nocturnal Trial, Frequent Hemodialysis Network: Nocturnal Trial | 2026-02-14 02:07:23 | 0 | |||||
|
Program to Reduce Incontinence by Diet and Exercise Resource Report Resource Website 5000+ mentions |
Program to Reduce Incontinence by Diet and Exercise (RRID:SCR_009018) | PRIDE | clinical trial, resource | Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence. | female, adult human, weight reduction, intervention, behavior, diet, exercise, motivation, weight maintenance |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of California at San Francisco; California; USA |
Urinary incontinence, Obesity, Weight loss, Overweight, Aging | NIDDK UO1 DK67860 | PMID:20664387 PMID:20680012 PMID:19179316 PMID:20643425 |
nlx_152847 | SCR_009018 | PRIDE (Program to Reduce Incontinence by Diet and Exercise) | 2026-02-14 02:08:00 | 6544 | |||||
|
ACCORD Resource Report Resource Website 100+ mentions |
ACCORD (RRID:SCR_009015) | ACCORD | clinical trial, resource | Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study. | middle adult human, late adult human, glycemic control, lowering lipid drug, blood pressure, lipid, clinical |
is related to: NIDDK Information Network (dkNET) has parent organization: National Heart Lung and Blood Institute |
Cardiovascular disease, Stroke, Type 2 diabetes, Diabetes, Aging | NHLBI ; NIDDK ; NEI ; CDC ; NIA |
PMID:23490598 PMID:23253271 PMID:23238658 PMID:22723583 PMID:22646230 |
nlx_152746 | SCR_009015 | Action to Control Cardiovascular Disease Risk in Diabetes | 2026-02-14 02:07:33 | 173 | |||||
|
HOMER Resource Report Resource Website 5000+ mentions |
HOMER (RRID:SCR_010881) | HOMER | software application, sequence analysis software, data processing software, software resource, data analysis software | Software tools for Motif Discovery and next-gen sequencing analysis. Used for analyzing ChIP-Seq, GRO-Seq, RNA-Seq, DNase-Seq, Hi-C and numerous other types of functional genomics sequencing data sets. Collection of command line programs for unix style operating systems written in Perl and C++. | motif, discovery, next, generation, sequencing, analysis, genomic, data |
is listed by: OMICtools is related to: findMotif.pl has parent organization: University of California at San Diego; California; USA |
NURSA consortium grant ; NIH HC088093; NIDDK DK063491; NCI CA52599; NIGMS P50 GM081892; Foundation Leducq Transatlantic Network Grant |
PMID:20513432 | OMICS_00483 | http://biowhat.ucsd.edu/homer/index.html | SCR_010881 | HOMER, Hypergeometric Optimization of Motif EnRichment, Homer, Homer v4.5 | 2026-02-15 09:20:21 | 5370 | |||||
|
University of Chicago Digestive Diseases Research Core Center Resource Report Resource Website 1+ mentions |
University of Chicago Digestive Diseases Research Core Center (RRID:SCR_015601) | DDRCC | organization portal, training resource, data or information resource, portal | Center whose goals include fostering collaboration among basic and clinical investigators, facilitating the use of new technologies in the study of treatment of digestive diseases, and providing education and training for improved treatment and diagnosis. | DDRCC, digestive disease, uchicago |
is listed by: NIDDK Information Network (dkNET) is parent organization of: University of Chicago Digestive Diseases Research Core Center Integrated Translational Research Core is parent organization of: University of Chicago Digestive Diseases Research Core Center Administrative Core is parent organization of: University of Chicago Digestive Diseases Research Core Center Host-Microbe Core is parent organization of: University of Chicago Digestive Diseases Research Core Center Tissue and Cell Imaging Core is parent organization of: University of Chicago Digestive Diseases Research Core Center Tissue Engineering and Cell Models Core has organization facet: University of Chicago Digestive Diseases Research Core Center Administrative Core has organization facet: University of Chicago Digestive Diseases Research Core Center Integrated Translational Research Core has organization facet: University of Chicago Digestive Diseases Research Core Center Tissue Engineering and Cell Models Core has organization facet: University of Chicago Digestive Diseases Research Core Center Host-Microbe Core has organization facet: University of Chicago Digestive Diseases Research Core Center Tissue and Cell Imaging Core is organization facet of: Digestive Disease Centers |
digestive disease | NIDDK P30 DK042086 | Available to the research community | SCR_015601 | 2026-02-15 09:21:21 | 1 | |||||||
|
Diabetes Prevention Program Resource Report Resource Website |
Diabetes Prevention Program (RRID:SCR_001501) | DPP | clinical trial, database, data or information resource, bibliography, resource | Multicenter clinical research study aimed at discovering whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in study participants. At the beginning of the DPP, all 3,234 study participants were overweight and had blood glucose levels higher than normal but not high enough for a diagnosis of diabetesa condition called prediabetes. In addition, 45 percent of the participants were from minority groups-African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, or Pacific Islander-at increased risk of developing diabetes. The DPP found that participants who lost a modest amount of weight through dietary changes and increased physical activity sharply reduced their chances of developing diabetes. Taking metformin also reduced risk, although less dramatically. In the DPP, participants from 27 clinical centers around the United States were randomly divided into different treatment groups. The first group, called the lifestyle intervention group, received intensive training in diet, physical activity, and behavior modification. By eating less fat and fewer calories and exercising for a total of 150 minutes a week, they aimed to lose 7 percent of their body weight and maintain that loss. The second group took 850 mg of metformin twice a day. The third group received placebo pills instead of metformin. The metformin and placebo groups also received information about diet and exercise but no intensive motivational counseling. A fourth group was treated with the drug troglitazone (Rezulin), but this part of the study was discontinued after researchers discovered that troglitazone can cause serious liver damage. The participants in this group were followed but not included as one of the intervention groups. In the years since the DPP was completed, further analyses of DPP data continue to yield important insights into the value of lifestyle changes in helping people prevent type 2 diabetes and associated conditions. For example, one analysis confirmed that DPP participants carrying two copies of a gene variant, or mutation, that significantly increased their risk of developing diabetes benefited from lifestyle changes as much as or more than those without the gene variant. Another analysis found that weight loss was the main predictor of reduced risk for developing diabetes in DPP lifestyle intervention group participants. The authors concluded that diabetes risk reduction efforts should focus on weight loss, which is helped by increased exercise. | prevention, lifestyle, metformin, intervention, dietary change, physical activity, minority, african-american, alaska native, american indian, asian american, hispanic, latino, pacific islander, male, female, slide, adult human, late adult human, dna |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: George Washington University; Washington D.C.; USA |
Type 2 diabetes, Prediabetes, Overweight, Non-insulin-dependent diabetes mellitus | NIDDK 1ZIADK075078-04 | Free, Freely available | nlx_152799 | SCR_001501 | 2026-02-15 09:18:07 | 0 | ||||||
|
TIGER Data Portal Resource Report Resource Website 10+ mentions |
TIGER Data Portal (RRID:SCR_023626) | disease-related portal, topical portal, data or information resource, portal | Resource enables integrative exploration of genetic and epigenetic basis of development of Type 2 Diabetes, together with other associated functional, molecular and clinical data, centered in biology and role of pancreatic beta cells.The gene expression regulatory variation landscape of human pancreatic islets. | Type 2 Diabetes, genetic and epigenetic, functional data, molecular data, clinical data, pancreatic beta cells. | is related to: T2DSystems | Type 2 Diabetes | European Union Horizon 2020 ; Spanish government ; Swiss State Secretariat for Education‚ Research and Innovation ; American Diabetes Association Innovative and Clinical Translational Award ; Research England ; Wellcome Trust ; NIDDK U01 DK105535; NIDDK U01 DK085545 |
PMID:34644572 | SCR_023626 | Translational Human Pancreatic Islet Genotype Tissue-Expression Resource | 2026-02-15 09:23:13 | 18 | |||||||
|
NIDDK Inflammatory Bowel Disease Genetics Consortium Resource Report Resource Website 1+ mentions |
NIDDK Inflammatory Bowel Disease Genetics Consortium (RRID:SCR_001461) | IBDGC, NIDDKIBDGC | material resource, cell repository, biomaterial supply resource | Repository of biospecimen and phenotype data collected from Crohn's disease and ulcerative colitis cases and controls recruited at six sites throughout North America that are available to the scientific community. Phenotyping is performed using a standardized protocol, and lymphoblastoid cell lines are established for each subject. Phenotype data for each subject are collected by the Consortium's Data Coordinating Center (DCC), and phenotype data for all subjects with DNA samples are available. The resulting DNA samples have already been utilized by the Consortium to complete various association studies, including genome-wide association studies using dense genotyping arrays. Researchers can obtain DNA samples and phenotype, genotype, and pedigree data through the Data Repository. GWAS data must be requested through dbGAP. The IBDGC is involved with independent genetic research studies and actively works with members of the IBD and genetic communities on collaborative projects. They are also members of the International IBD Genetics Consortium. Phenotype Tools: The Consortium Phenotype Committee, led by Dr. Hillary Steinhart designed and validated paper forms to collect extensive phenotype data on Crohn's Disease and ulcerative colitis. Consortium phenotype tools are available for use by non-Consortium members. | dna, cell line, serum, lymphocyte, lymphoblastoid cell line, gene, loci, genetic analysis, blood, phenotype, genome-wide association study, genotype, pedigree, metadata standard, genotyping array |
uses: NCBI database of Genotypes and Phenotypes (dbGap) is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) has parent organization: Yale School of Medicine; Connecticut; USA |
Inflammatory Bowel Disease, Crohn's disease, Ulcerative colitis, Control, Family member | NIDDK U01 DK062429 | Free, Freely Available | nlx_152706 | http://medicine.yale.edu/intmed/ibdgc/ | SCR_001461 | IBD Genetics Consortium, NIDDKIBD Genetics Consortium, Inflammatory Bowel Disease Genetic Consortium | 2026-02-15 09:18:06 | 1 | ||||
|
Lifestyle Interventions for Expectant Moms (LIFE-Moms) Resource Report Resource Website |
Lifestyle Interventions for Expectant Moms (LIFE-Moms) (RRID:SCR_014376) | LIFE-Moms | organization portal, resource, data or information resource, portal | A consortium whose overall goal is to identify effective behavioral and lifestyle interventions that will improve weight, glycemic control and other pregnancy-related outcomes in obese and overweight pregnant women, and determine whether these interventions reduce obesity and metabolic abnormalities in their children. The study/consortium is comprised of seven clinical centers, with each clinical center conducting its own trial. Additional information on the consortium and individual trials is located in the Consortium Summaries tab. | pregnant, pregnancy, obesity, metabolic abnormality, behavioral intervention, lifestyle intervention, clinical trial |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Obesity | NIDDK ; NHLBI ; NICHD ; National Center for Complementary and Integrative Health ; Office of Research on Womens Health ; Office of Behavioral and Social Sciences Research |
Synopses available, Users may access trial data at clinicaltrial.gov | http://www.niddk.nih.gov/research-funding/research-resources/Pages/default.aspx | SCR_014376 | Lifestyle Interventions for Expectant Moms | 2026-02-15 09:20:53 | 0 | |||||
|
Restoring Insulin Secretion Consortium (RISE) Resource Report Resource Website |
Restoring Insulin Secretion Consortium (RISE) (RRID:SCR_014383) | RISE | organization portal, portal, database, consortium, data or information resource | Consortium which includes 3 studies, each assessing the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after treatment in those with prediabetes and early type 2 diabetes. | prediabetes, type 2 diabetes, consortium, aggressive glucose lowering, beta cell function, Diabetes |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources is listed by: Diabetes Research Centers is listed by: NIDDK Central Repository |
NIDDK | SCR_014383 | Restoring Insulin Secretion Consortium | 2026-02-15 09:21:01 | 0 | ||||||||
|
ReBuilding a Kidney Resource Report Resource Website 1+ mentions |
ReBuilding a Kidney (RRID:SCR_014442) | RBK | organization portal, portal, funding resource, data or information resource, resource | A consortium of research projects working to optimize approaches for the isolation, expansion, and differentiation of appropriate kidney cell types and their integration into complex structures that replicate human kidney function. Their goal is to coordinate and integrate research to support the development and implementation of strategies such as de novo repair of nephrons, the re-generation of nephrons, and the in vitro engineering of a biological kidney to enhance renal repair and promote the generation of new nephrons in the postnatal organ. Investigators may apply for funding of a kidney-related project through the RBK Partnership Project. Funded projects would join the consortium. | consortium, kidney, rebuild, kidney cell type, human, kidney function, nephron, engineer, renal repair | is listed by: NIDDK Information Network (dkNET) | NIDDK | PMID:28096308 | Available to the research community, Account needed to view data | SCR_014442 | (Re)Building a Kidney | 2026-02-15 09:20:54 | 3 | ||||||
|
University of California San Diego - University of California Los Angeles Diabetes Research Center Resource Report Resource Website |
University of California San Diego - University of California Los Angeles Diabetes Research Center (RRID:SCR_015100) | portal, service resource, data or information resource, access service resource, topical portal, disease-related portal, resource | Research center across five institutions for clinical research in diabetes. Collaborators include UC San Diego's School of Medicine, Salk Institute, Cedars-Sinai Medical Center, UC Los Angeles' School of Medicine, and LA Biomedical Research Center. | diabetes research, research collaboration, research network, metabolic research, southern california |
is listed by: NIDDK Information Network (dkNET) is affiliated with: Diabetes Research Centers is parent organization of: University of California San Diego - University of California Los Angeles Diabetes Research Center Human Genetics Core Facility is parent organization of: University of California San Diego - University of California Los Angeles Diabetes Research Center Targeted Pathway Analysis Core Facility is parent organization of: University of California San Diego - University of California Los Angeles Diabetes Research Center Genomics and Epigenetics Core Facility is parent organization of: University of California San Diego - University of California Los Angeles Diabetes Research Center Transgenic and Knockout Mouse Core Facility is parent organization of: University of California San Diego - University of California Los Angeles Diabetes Research Center Metabolic and Molecular Physiology Core Facility has organization facet: University of California San Diego - University of California Los Angeles Diabetes Research Center Transgenic and Knockout Mouse Core Facility has organization facet: University of California San Diego - University of California Los Angeles Diabetes Research Center Metabolic and Molecular Physiology Core Facility has organization facet: University of California San Diego - University of California Los Angeles Diabetes Research Center Genomics and Epigenetics Core Facility has organization facet: University of California San Diego - University of California Los Angeles Diabetes Research Center Human Genetics Core Facility has organization facet: University of California San Diego - University of California Los Angeles Diabetes Research Center Targeted Pathway Analysis Core Facility is organization facet of: Diabetes Research Centers |
Diabetes | NIDDK P30DK063491 | Available to the research community | http://derc.ucsd.edu/index.html | SCR_015100 | 2026-02-15 09:20:49 | 0 | |||||||
|
Mayo Clinic Center for Cell Signaling in Gastroenterology Resource Report Resource Website |
Mayo Clinic Center for Cell Signaling in Gastroenterology (RRID:SCR_015224) | portal, service resource, data or information resource, access service resource, topical portal, disease-related portal, resource | Center whose mission is to improve understanding of the signaling pathways that control the function of gastrointestinal cells in health and disease. It serves as a hub that provides access to research resources and expertise to multidisciplinary groups of basic scientists and clinical researchers. | C-SiG, gastroenterology, cell signaling, gastrointestinal diseases |
is listed by: NIDDK Information Network (dkNET) has parent organization: Mayo Clinic is parent organization of: Mayo Clinic Center for Cell Signaling in Gastroenterology Clinical Core is parent organization of: Mayo Clinic Center for Cell Signaling in Gastroenterology Optical Microscopy Core has organization facet: Mayo Clinic Center for Cell Signaling in Gastroenterology Clinical Core has organization facet: Mayo Clinic Center for Cell Signaling in Gastroenterology Gene Editing and Cell Engineering Core has organization facet: Mayo Clinic Center for Cell Signaling in Gastroenterology Optical Microscopy Core is organization facet of: Digestive Disease Centers |
NIDDK P30DK084567 | Available to Mayo Clinic researchers, Limited availability to the research community | SCR_015224 | 2026-02-15 09:21:21 | 0 | |||||||||
|
Georgia Center for Diabetes Translation Research Resource Report Resource Website |
Georgia Center for Diabetes Translation Research (RRID:SCR_015185) | portal, service resource, data or information resource, access service resource, topical portal, disease-related portal, resource | Research center for translational research on type 2 diabetes with a strong emphasis on translation into real world health care settings and communities. | type 2 diabetes research, implementation research, translational research, emory university, georgia tech |
is listed by: NIDDK Information Network (dkNET) is affiliated with: Centers for Diabetes Translation Research has parent organization: Emory University; Georgia; USA has parent organization: Georgia Institute of Technology; Georgia; USA has parent organization: Morehouse School of Medicine; Georgia; USA is parent organization of: Georgia Center for Diabetes Translation Research Design and Evaluation Core Facility is parent organization of: Georgia Center for Diabetes Translation Research Disparities Core is parent organization of: Georgia Center for Diabetes Translation Research Engagement and Behavior Change Core has organization facet: Georgia Center for Diabetes Translation Research Design and Evaluation Core Facility has organization facet: Georgia Center for Diabetes Translation Research Engagement and Behavior Change Core has organization facet: Georgia Center for Diabetes Translation Research Disparities Core is organization facet of: Centers for Diabetes Translation Research |
Diabetes | NIDDK P30DK111024 | Available to the research community | SCR_015185 | 2026-02-15 09:20:50 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Email: info_at_ dknet.org
